fluorodeoxyglucose f18 has been researched along with everolimus in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Cejka, D; Fritzer-Szekeres, M; Fueger, BJ; Fuereder, T; Kuntner, C; Langer, O; Mueller, M; Preusser, M; Strommer, S; Wacheck, V; Wanek, T; Werzowa, J; Zsebedics, M | 1 |
| Bangard, C; Boellaard, R; Dietlein, M; Dimitrijevic, S; Eschner, W; Giaccone, G; Gross, SH; Hayes, W; Hoekstra, OS; Hoetjes, N; Kobe, C; Lammertsma, AA; Nogová, L; Pellas, T; Schmidt, K; Thomas, RK; Wolf, J; Zander, T | 1 |
| Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W | 1 |
| Bellan, E; Biasco, G; Boschi, S; Castelli, M; Castellucci, P; Di Battista, M; Fanti, S; Gnocchi, C; Landuzzi, L; Lollini, PL; Nanni, C; Nannini, M; Nicoletti, G; Pantaleo, MA; Quarta, C; Rubello, D | 1 |
| Brouwers, AH; de Vries, EG; Fiebrich, HB; Hospers, GA; Links, TP; Remkes, WS; Siemerink, EJ | 1 |
| Aichler, M; Baumgart, A; Buck, A; Dechow, T; Feuchtinger, A; Graf, N; Herrmann, K; Jünger, A; Keller, U; Li, Z; Peschel, C; Schwaiger, M; Walch, A | 1 |
| Avadhani, AN; Ciunci, CA; Divgi, CR; Englander, S; Flaherty, KT; Giantonio, BJ; Harlacker, K; Kang, HC; O'Dwyer, PJ; Perini, RF; Redlinger, M; Rosen, MA; Schnall, M; Song, HK; Sun, W; Troxel, A | 1 |
| Appelbaum, DE; Chen, JL; Cowey, CL; Kocherginsky, M; McDermott, DF; Rathmell, WK; Stadler, WM | 1 |
| Fisker Hag, AM; Haagen Nielsen, C; Johnbeck, CB; Kjaer, A; Knigge, U; Munk Jensen, M | 1 |
| Bang, YJ; Cho, BC; Chung, JS; Han, JY; Kang, JH; Kim, DW; Kim, H; Kim, MJ; Kwon, JH; Oh, DY; Park, KU; Shin, SH | 1 |
| Beer, TM; Courtney, KD; Elfiky, AA; Kantoff, P; Loda, M; Manola, JB; Oh, WK; Priolo, C; Ross, R; Ryan, CW; Taplin, ME; Van den Abbeele, AD; Yap, JT | 1 |
| Auffermann, WF; Bechara, R; Behera, M; Chen, Z; Deng, X; Force, SD; Fu, H; Fu, RW; Gal, AA; Harvey, RD; Khuri, FR; Kim, S; Mendel, J; Miller, DL; Owonikoko, TK; Pickens, A; Ramalingam, SS; Rogatko, A; Rossi, MR; Saba, NF; Sica, GL; Sun, SY; Tighiouart, M; Torres, WE | 1 |
| Hasumi, H; Hattori, Y; Hayashi, N; Inoue, T; Ito, H; Kaneta, T; Kawahara, T; Kobayashi, K; Kondo, K; Makiyama, K; Miyoshi, Y; Nakaigawa, N; Namura, K; Osaka, K; Tateishi, U; Teranishi, JI; Uemura, H; Ueno, D; Yao, M; Yokomizo, Y; Yumura, Y | 1 |
| Chen, TC; Lin, G; Lin, KJ; Wang, F; Yeh, TS; Yen, TC | 1 |
| Demir, E; Karaoglan, C; Sair, B; Sever, MS; Turkmen, A; Yazici, H; Yegen, G | 1 |
| Bruna-Muraille, C; Dejust, S; Eymard, JC; Morland, D; Papathanassiou, D; Savoye, AM; Yazbek, G | 1 |
| Akhurst, T; Hicks, RJ; Jefford, M; Kuru, N; Liauw, W; Link, E; Lung, MS; Michael, M; Pavlakis, N; Thomson, B; Wyld, DK | 1 |
| Abdulla, DSY; Backes, H; Behringer, D; Buettner, R; Eichstaedt, M; Fischer, RN; Franklin, J; Frechen, S; Fuhr, U; Gardizi, M; Junge, L; Kaminsky, B; Kinzig, M; Kobe, C; Limburg, M; Mattonet, C; Merkelbach-Bruse, S; Michels, S; Nogova, L; Ouyang, D; Persigehl, T; Rokitta, D; Scheffler, M; Schnell, R; Sörgel, F; Sos, ML; Stelzer, C; Suleiman, AA; Taubert, M; Tian, Y; Wolf, J | 1 |
9 trial(s) available for fluorodeoxyglucose f18 and everolimus
| Article | Year |
|---|---|
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus.
Topics: Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Glucose; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Time Factors; TOR Serine-Threonine Kinases | 2009 |
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Everolimus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sirolimus; Temozolomide | 2011 |
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Dose-Response Relationship, Drug; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Sirolimus; Treatment Outcome; Tumor Burden | 2013 |
A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Positron-Emission Tomography; Sirolimus; Treatment Outcome; Tumor Burden | 2014 |
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Everolimus; Fluorodeoxyglucose F18; Humans; Male; Maximum Tolerated Dose; Middle Aged; Positron-Emission Tomography; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Topics: Adult; Aged; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Survival Rate | 2020 |
Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins p21(ras); Sorafenib | 2020 |
10 other study(ies) available for fluorodeoxyglucose f18 and everolimus
| Article | Year |
|---|---|
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carrier Proteins; Cell Line, Tumor; Enzyme Inhibitors; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Positron-Emission Tomography; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Enzyme Inhibitors; Everolimus; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Mice; Mice, Knockout; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiopharmaceuticals; Receptor, Platelet-Derived Growth Factor alpha; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Blood Glucose; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Hypoglycemia; Insulin; Insulin Secretion; Insulinoma; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Positron-Emission Tomography; Sirolimus; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases | 2011 |
FLT-PET is superior to FDG-PET for very early response prediction in NPM-ALK-positive lymphoma treated with targeted therapy.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Dideoxynucleosides; Enzyme Inhibitors; Everolimus; Female; Flow Cytometry; Fluorine Radioisotopes; Fluorodeoxyglucose F18; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lymphoma, Large-Cell, Anaplastic; Mice; Mice, SCID; Positron-Emission Tomography; Protein-Tyrosine Kinases; Resorcinols; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Monitoring; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Mice; Multimodal Imaging; Neuroendocrine Tumors; Positron-Emission Tomography; Tomography, X-Ray Computed; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2014 |
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Tomography, X-Ray Computed | 2017 |
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Choline; Choline Kinase; Deoxycytidine; Drug Synergism; Everolimus; Fluorodeoxyglucose F18; Gemcitabine; Humans; Male; Metabolome; Mice; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Extreme hypercalcemia in a kidney transplant recipient.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Everolimus; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Hypercalcemia; Kidney Transplantation; Lymphoproliferative Disorders; Male; Positron-Emission Tomography; Prednisone; Renal Dialysis; Rituximab; Shock, Septic; Transplant Recipients; Vincristine | 2018 |
Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Everolimus; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Lung Diseases, Interstitial; Middle Aged; Positron Emission Tomography Computed Tomography; TOR Serine-Threonine Kinases; Tumor Burden | 2018 |